SIGLEC9 and chronic obstructive pulmonary disease: SIGLEC9 was reported to possibly induce negative feedback by increasing complementarily, which limits neutrophil activation in COPD; moreover, it competitively inhibits the ligands that bind to SIGLEC9 [66].